XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.62

+1.6%

Dec 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (10528)	6/22/1999 9:11:00 PM
From: Bluegreen	Read Replies (1) of 17367

George, article stated>>>>>>>>>He said: "Mortality varies very much between centres. If you are in the best possible place, being treated from very early on, you will do well - mortality will be under five per cent.<<<<< The only thing I can come up with is some centers may be quicker and more equipped to hack off digits and limbs. That is my conclusion. Now, even if you have low mortality but a peripheral modified patient, where do you go from there? What if only slightly lower mortality but much more peripheral modification in Neuprex treated group because they held on longer to go under the saw? What would the FDA and UK regulatory pundits do? Only my opinions and conclusions. I could be totally wrong. Standard K disclaimer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next